Alliance for Regenerative Medicine - Disease Spotlight

Disease Facts:
Description:                  Amyotrophic Lateral Sclerosis (ALS)
+ Causes nerve cell death
that leads to disability,     + A Devastating, Debilitating Disease With No Known Cure
paralysis, and eventual
death                         Better known as Lou Gehrig’s         advanced cases treatment             to drug development for ALS do
                              disease, ALS (amyotrophic            expenses can be as high              not address the underlying
Patients:
                              lateral sclerosis) afflicts an       $200,000 annually, representing      causes of the disease, regenera-
+ 30,000 in the US; 5,000
                              estimated 30,000 Americans           an aggregate direct cost to          tive medicine technologies
new patients diagnoses
                              with approximately 5,600             the healthcare system of more        could potentially transform the
each year
                              additional cases being               than $6 billion per year. Total      current standard of care by
Cause:                        diagnosed each year. ALS             economic impact is difficult to      halting or reversing progression
+ Unknown                     causes the motor neurons that        measure because — in addition        by slowing motor neuron death.
                              control the movement of              to the cost of medicine, devices,    These technologies may even
Progression:
                              muscles to begin to deteriorate      and hospital visits — most of        have the potential to replace or
+ Life expectancy is 2-5
                              and die, leaving patients            the care involved in ALS is          regenerate lost cells over time,
years after diagnosis
                              progressively weaker resulting       provided at home by family           allowing patients to maintain a
Current Cost of Care:         in worsening disability and          members. Many individuals quit       normal quality of life. Brain-
+ Direct and indirect                                              their jobs in order to stay at       Storm Therapeutics Inc., a RM
                              eventual death. Once diagnosed
costs total over $6 billion                                        home with the patient at later       company, is conducting a Phase
                              the life expectancy averages 2
per year                                                           stages of the disease or must        I/II trial in Israel for the use of
                              to 5 years, though a very small
                              percentage of people will live 20    pay for hospice care.                NurOwn, a treatment that uses
RM and ALS:                                                                                             autologous mesenchymal stem
                              years or more with the disease.
+ 4 RM companies with                                              Currently the only available         cells present in the patient’s
                              While people with ALS may
active ALS programs                                                treatments do not actually           own bone marrow to create
                              have a reasonable quality of life
+ 6 clinical trials ongoing                                        treat ALS, but instead attempt       dopamine and NTF (neuro-
                              for a year or more after
or completed using stem                                            to alleviate the disruptive and
                              diagnosis, the neurodegenera-                                             trophic factors) producing cells
cells for treatment or to                                          debilitating side effects of the
                              tive nature of the disease is                                             that stall the degeneration of
create disease models to                                           disease. These include reduced
                              considered irreversible with                                              motor neurons. Another
screen for new drugs                                               mobility, impaired speech,
                              current treatments and invaria-                                           company, Neuralstem Inc., is
                                                                   breathing problems, and
+ Current programs are        bly results in the death of the                                           currently working with Emory
                                                                   dietary challenges. These
investigating the use of      patient. In addition, the                                                 University to conduct a Phase I
                                                                   heavily affect the quality of life
mesenchymal (bone             psychological effects of the                                              clinical trial of fetal-derived
                                                                   of the patient as they must be
marrow) and fetal cells to    disease are devastating, as most                                          stem cells for another
                                                                   addressed with often invasive
slow disease progression      patients are quadriplegic in the                                          treatment of ALS. Although
                                                                   or expensive devices like
                              end stages of the disease, but                                            these innovative therapies are
                                                                   ventilators, feeding tubes, lifts,
                              still maintain high levels                                                still years away from becoming
                                                                   and digital speech aids.
                              awareness and their basic                                                 commercially available, they
                                                                   Treating these secondary
                              senses as their body functions                                            could potentially greatly
     The Alliance for                                              conditions creates not only
                              progressively shut down.                                                  improve the quality of life for
 Regenerative Medicine                                             incredibly high costs of care for
                                                                                                        ALS sufferers and save families
  (ARM) was formed to         At late stages, the disease is       the disease but also has a huge
                                                                                                        and the healthcare system
  advance regenerative        incredibly costly, as patients       impact on the quality of life for
                                                                                                        billions of dollars over time.
medicine by representing      typically require intensive care     both patients and care givers.
   and supporting the         and long hospitalizations. In        While the traditional approach
      community of
  companies, academic         + Regenerative Medicine—In Brief
  research institutions,
                              What is regenerative medicine?       tissue and renew biologic            products addressing many more
patient advocacy groups,
                              Regenerative medicine (RM) is a      function in the body is what         conditions advancing in clinical
 foundations, and other       rapidly evolving interdisciplinary   distinguishes RM from other          trials. RM holds the promise of
organizations before the      field in health care that trans-     types of treatments and brings       treating a broad range of dis-
    Congress, federal         lates fundamental knowledge in       new hope for dramatically            eases that collectively represent
agencies and the general      biology, chemistry and physics       improving clinical outcomes and      a substantial burden to our
         public.              into materials, devices, systems     curing disease.                      healthcare system, including
                              and therapeutic strategies,          What diseases can RM treat?          acute and chronic conditions
  For more information,       including cell-based therapies,                                           such as diabetes, congestive
                                                                   RM products are currently on
 please visit us online at:   which augment, repair, replace       the market for the treatment of      heart failure, Parkinson’s
   www.alliancerm.org         or regenerate organs and             wounds, cartilage defects, and       disease, stroke, renal disease,
                              tissues. The ability to repair       diabetic foot ulcers, with           spinal cord injury, and ALS.

Arm ALS

  • 1.
    Alliance for RegenerativeMedicine - Disease Spotlight Disease Facts: Description: Amyotrophic Lateral Sclerosis (ALS) + Causes nerve cell death that leads to disability, + A Devastating, Debilitating Disease With No Known Cure paralysis, and eventual death Better known as Lou Gehrig’s advanced cases treatment to drug development for ALS do disease, ALS (amyotrophic expenses can be as high not address the underlying Patients: lateral sclerosis) afflicts an $200,000 annually, representing causes of the disease, regenera- + 30,000 in the US; 5,000 estimated 30,000 Americans an aggregate direct cost to tive medicine technologies new patients diagnoses with approximately 5,600 the healthcare system of more could potentially transform the each year additional cases being than $6 billion per year. Total current standard of care by Cause: diagnosed each year. ALS economic impact is difficult to halting or reversing progression + Unknown causes the motor neurons that measure because — in addition by slowing motor neuron death. control the movement of to the cost of medicine, devices, These technologies may even Progression: muscles to begin to deteriorate and hospital visits — most of have the potential to replace or + Life expectancy is 2-5 and die, leaving patients the care involved in ALS is regenerate lost cells over time, years after diagnosis progressively weaker resulting provided at home by family allowing patients to maintain a Current Cost of Care: in worsening disability and members. Many individuals quit normal quality of life. Brain- + Direct and indirect their jobs in order to stay at Storm Therapeutics Inc., a RM eventual death. Once diagnosed costs total over $6 billion home with the patient at later company, is conducting a Phase the life expectancy averages 2 per year stages of the disease or must I/II trial in Israel for the use of to 5 years, though a very small percentage of people will live 20 pay for hospice care. NurOwn, a treatment that uses RM and ALS: autologous mesenchymal stem years or more with the disease. + 4 RM companies with Currently the only available cells present in the patient’s While people with ALS may active ALS programs treatments do not actually own bone marrow to create have a reasonable quality of life + 6 clinical trials ongoing treat ALS, but instead attempt dopamine and NTF (neuro- for a year or more after or completed using stem to alleviate the disruptive and diagnosis, the neurodegenera- trophic factors) producing cells cells for treatment or to debilitating side effects of the tive nature of the disease is that stall the degeneration of create disease models to disease. These include reduced considered irreversible with motor neurons. Another screen for new drugs mobility, impaired speech, current treatments and invaria- company, Neuralstem Inc., is breathing problems, and + Current programs are bly results in the death of the currently working with Emory dietary challenges. These investigating the use of patient. In addition, the University to conduct a Phase I heavily affect the quality of life mesenchymal (bone psychological effects of the clinical trial of fetal-derived of the patient as they must be marrow) and fetal cells to disease are devastating, as most stem cells for another addressed with often invasive slow disease progression patients are quadriplegic in the treatment of ALS. Although or expensive devices like end stages of the disease, but these innovative therapies are ventilators, feeding tubes, lifts, still maintain high levels still years away from becoming and digital speech aids. awareness and their basic commercially available, they Treating these secondary senses as their body functions could potentially greatly The Alliance for conditions creates not only progressively shut down. improve the quality of life for Regenerative Medicine incredibly high costs of care for ALS sufferers and save families (ARM) was formed to At late stages, the disease is the disease but also has a huge and the healthcare system advance regenerative incredibly costly, as patients impact on the quality of life for billions of dollars over time. medicine by representing typically require intensive care both patients and care givers. and supporting the and long hospitalizations. In While the traditional approach community of companies, academic + Regenerative Medicine—In Brief research institutions, What is regenerative medicine? tissue and renew biologic products addressing many more patient advocacy groups, Regenerative medicine (RM) is a function in the body is what conditions advancing in clinical foundations, and other rapidly evolving interdisciplinary distinguishes RM from other trials. RM holds the promise of organizations before the field in health care that trans- types of treatments and brings treating a broad range of dis- Congress, federal lates fundamental knowledge in new hope for dramatically eases that collectively represent agencies and the general biology, chemistry and physics improving clinical outcomes and a substantial burden to our public. into materials, devices, systems curing disease. healthcare system, including and therapeutic strategies, What diseases can RM treat? acute and chronic conditions For more information, including cell-based therapies, such as diabetes, congestive RM products are currently on please visit us online at: which augment, repair, replace the market for the treatment of heart failure, Parkinson’s www.alliancerm.org or regenerate organs and wounds, cartilage defects, and disease, stroke, renal disease, tissues. The ability to repair diabetic foot ulcers, with spinal cord injury, and ALS.